1. GDUFA (2022) Generic Drug User Fee Amendments (GDUFA) science and research priority initiatives for Fiscal Year
2. (FY) 2022. https://www.fda.gov/media/154487/download
3. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15:657–680. https://doi.org/10.1007/BF01068419
4. U.S. Food and Drug Administration (2021) Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry. https://www.fda.gov/media/87219/download
5. European Medicines Evaluation Agency (2010) Guideline on the investigation of bioequivalence. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf